Asif Ali Protagonist Therapeutics, Inc (PTGX) insider trading activity

Asif Ali is Chief Financial Officer of Protagonist Therapeutics, Inc. Currently has a direct ownership of 86,665 shares of PTGX, which is worth approximately $7.33 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 25,600 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.7K

41.92% 3M change

29.86% 12M change

Total Value Held $7.33 Million

Asif Ali Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	BUY Grant, award, or other acquisition	-	25,600 Added 22.8%	86,665 Common Stock
Apr 22 2025	SELL Open market or private sale	$80,776 $46.0 p/Share	1,756 Reduced 2.8%	61,065 Common Stock
Mar 12 2025	SELL Open market or private sale	$1,462,553 $58.73 p/Share	24,903 Reduced 28.39%	62,821 Common Stock
Mar 12 2025	BUY Exercise of conversion of derivative security	$390,479 $15.68 p/Share	24,903 Added 22.11%	87,724 Common Stock
Jan 16 2025	SELL Open market or private sale	-	3,918 Reduced 5.87%	62,821 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	31,779 Added 32.26%	66,739 Common Stock
Sep 11 2024	SELL Open market or private sale	$632,459 $44.53 p/Share	14,203 Reduced 28.89%	34,960 Common Stock

Sep 11 2024	BUY Exercise of conversion of derivative security	$188,160 $15.68 p/Share	12,000 Added 20.35%	46,960 Common Stock
Apr 18 2024	SELL Open market or private sale	$30,985 $25.11 p/Share	1,234 Reduced 3.21%	37,163 Common Stock
Mar 01 2024	SELL Open market or private sale	$459,925 $32.28 p/Share	14,248 Reduced 27.06%	38,397 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$146,040 $12.17 p/Share	12,000 Added 18.56%	52,645 Common Stock
Feb 29 2024	SELL Open market or private sale	$306,220 $30.81 p/Share	9,939 Reduced 19.65%	40,645 Common Stock
Jan 16 2024	SELL Payment of exercise price or tax liability	$35,762 $24.63 p/Share	1,452 Reduced 2.79%	50,584 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	21,000 Added 28.75%	52,036 Common Stock
May 31 2023	SELL Payment of exercise price or tax liability	$108,190 $26.07 p/Share	4,150 Reduced 11.79%	31,036 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	12,000 Added 25.43%	35,186 Common Stock
Apr 18 2023	SELL Payment of exercise price or tax liability	$27,596 $23.21 p/Share	1,189 Reduced 4.88%	23,186 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	10,625 Added 30.36%	24,375 Common Stock
Apr 18 2022	BUY Grant, award, or other acquisition	-	13,750 Added 50.0%	13,750 Common Stock

Asif Ali

Chief Financial Officer

Newark, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Value

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX

Account